ClinicalTrials.gg
CompletedNCT01139762Updated Feb 27, 2013Results posted

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

A Phase 3 interventional study of Tadalafil and Placebo in Benign Prostatic Hyperplasia and Enlarged Prostate, sponsored by Eli Lilly and Company. Completed at 65 sites in 13 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2013-02-27.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
696
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
3rd of 26
696 · median 258
Started
2010
with 2 others
Phase 3
10 of 26
none open now
Registered
11th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 3rd largest by enrollment, is one of 3 that started in 2010, is one of 10 in phase 3, and was the 11th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate enlargement.

03

Conditions studied

  • Benign Prostatic Hyperplasia
  • Enlarged Prostate

Browse trials for

Keywords

  • Benign Prostatic Hyperplasia (BPH)
  • Enlarged Prostate
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have not taken the following treatments within the indicated duration and agree not to use at any time during the study:

    • All other Benign Prostatic Hyperplasia (BPH) therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.
    • Overactive bladder therapy (including antimuscarinics) for at least 4 weeks prior to receiving study medication.
    • Erectile Dysfunction therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.
    • Finasteride or dutasteride use at any time.
  • Have bladder outlet obstruction as defined by a urinary peak flow rate (Qmax) of greater than or equal to 4 and less than or equal to 15 milliliters (mL)/second before receiving study drug.
  • Have prostate enlargement measured by ultrasound at screening.

Exclusion criteria

Exclusion Criteria:

  • Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer [Prostate-specific antigen (PSA) greater than 10 nanograms/milliliter (ng/mL) at the start of study].
  • Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).
  • Have problems with kidneys, liver, or nervous system
  • Have uncontrolled diabetes
  • Have had a stroke or a significant injury to brain or spinal cord.
  • Have scheduled or planned surgery during the course of the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
696 participants (actual)

Study arms

  • Experimental
    Tadalafil

    Drug: Tadalafil · Drug: Finasteride

  • Placebo comparator
    Placebo

    Drug: Placebo · Drug: Finasteride

Interventions

  • 5 milligrams (mg) administered orally, once daily for 26 weeks

    Also known as: Cialis, LY#450190

  • DrugPlacebo

    Administered orally, once daily for 26 weeks

  • 5mg administered orally, once daily for 26 weeks

06

What researchers measure

Primary outcomes

  1. Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks

    The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change in Total International Prostate Symptom Score (IPSS) From Baseline to 4 and 26 Weeks

    The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 26 weeks

  2. Change in International Prostate Symptom Score (IPSS) Subscores Index From Baseline to 4, 12, and 26 Weeks

    IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the 7-component IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore range from 0 to 15. IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score range from 0 to 20. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks

  3. Change in International Prostate Symptom Score (IPSS) Quality of Life Index From Baseline to 4, 12, and 26 Weeks

    IPSS Quality of Life Index assesses participant response to the following question: "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?" Response options are Delighted (0); Pleased (1); Mostly satisfied (2); Mixed-about equally satisfied and dissatisfied (3); Mostly dissatisfied (4); Unhappy (5); Terrible (6), with a total range of 0-6. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks

  4. Change in International Index of Erectile Function (IIEF) - Erectile Function Domain Scores From Baseline to 4, 12, and 26 Weeks

    Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks

  5. Change in International Index of Erectile Function (IIEF) - Overall Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks

    Self-reported overall satisfaction over the past 4 weeks. IIEF-Overall Satisfaction is the sum of Questions 13 and 14 of IIEF questionnaire. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks

  6. Change in International Index of Erectile Function (IIEF) - Intercourse Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks

    Self-reported intercourse satisfaction over the past 4 weeks. IIEF-intercourse satisfaction is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks

  7. Change in International Index of Erectile Function (IIEF) - Orgasmic Function Domain Scores From Baseline to 4, 12, and 26 Weeks

    Orgasmic Function domain scores is the sum of Questions 9 and 10 from the IIEF questionnaire. Scores range from 0 (low/no orgasm) to 5 (high orgasm) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher total scores indicate higher orgasm. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks

  8. Change in International Index of Erectile Function (IIEF) - Sexual Desire Domain Scores From Baseline to 4, 12, and 26 Weeks

    Sexual desire domain scores is the sum of Questions 11 and 12 from the IIEF questionnaire. Scores range from 1 (low/no desire) to 5 (high desire) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher desire. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks

  9. Patient Global Impression of Improvement (PGI-I) at 26 Weeks

    Patient Global Impression of Improvement (PGI-I) measures the participant's perception of improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).

    Time frame: 26 weeks

  10. Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 26 Weeks

    The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. It consists of 10 items on a Likert-like scale with scores ranging from 1 (higher satisfaction) to 5 (lower satisfaction), 1 item with score ranging from 0 (higher satisfaction) to 5 (lower satisfaction), and 2 yes/no questions. The mean score for each participant ranges from 0.9 (higher satisfaction) to 5.0 (lower satisfaction). Data presented are the average of mean scores for each treatment group.

    Time frame: 26 weeks

  11. Clinician Global Impression of Improvement (CGI-I) at 26 Weeks

    Clinician Global Impression of Improvement (CGI-I) measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).

    Time frame: 26 weeks

  12. Change in Post Void Residual (PVR) Volume From Baseline to 26 Weeks

    Postvoid Residual Volume (PVR) is determined using a portable, calibrated ultrasound device. It consists of the average of a minimum of 3 scans where the residual bladder volume was calculated by averaging the most accurate of the 3 imaging attempts.

    Time frame: Baseline, 26 weeks

  13. Change in International Index of Erectile Function (IIEF) Question 3 and 4 Scores From Baseline to 4, 12, and 26 Weeks

    IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

    Time frame: Baseline, 4 weeks, 12 weeks, 26 weeks

07

Results

Posted Feb 27, 2013

Participant flow

Washout and Placebo Lead-In Period
Participant flow — Washout and Placebo Lead-In Period
MilestoneScreening-Washout and Placebo Lead-InTadalafilPlacebo
Started107000
Completed69600
Not completed37400
Withdrew: Entry criteria not met25800
Withdrew: Adverse event100
Withdrew: Withdrawal by subject8300
Withdrew: Physician decision1200
Withdrew: Sponsor decision1000
Withdrew: Lost to follow-up1000
Double-Blind Randomized Active Treatment
Participant flow — Double-Blind Randomized Active Treatment
MilestoneScreening-Washout and Placebo Lead-InTadalafilPlacebo
Started0346350
Received at least 1 dose of study drug0345350
Completed0306286
Not completed04064
Withdrew: Adverse event0410
Withdrew: Death011
Withdrew: Entry criteria not met01417
Withdrew: Protocol violation028
Withdrew: Withdrawal by subject0613
Withdrew: Physician decision020
Withdrew: Sponsor decision056
Withdrew: Lack of efficacy035
Withdrew: Lost to follow-up034

Outcome measures

PrimaryChange in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks

The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks
units on a scaleTadalafilPlacebo
Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks-5.18 ± 0.32-3.76 ± 0.32
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.001 · Ls mean difference: -1.41 · 95% CI -2.27 to -0.55The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
SecondaryChange in Total International Prostate Symptom Score (IPSS) From Baseline to 4 and 26 Weeks

The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in Total International Prostate Symptom Score (IPSS) From Baseline to 4 and 26 Weeks
units on a scaleTadalafilPlacebo
4 weeks-3.95 ± 0.29-2.29 ± 0.28
26 weeks-5.51 ± 0.33-4.47 ± 0.33
SecondaryChange in International Prostate Symptom Score (IPSS) Subscores Index From Baseline to 4, 12, and 26 Weeks

IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the 7-component IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore range from 0 to 15. IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score range from 0 to 20. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 12 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in International Prostate Symptom Score (IPSS) Subscores Index From Baseline to 4, 12, and 26 Weeks
units on a scaleTadalafilPlacebo
IPSS storage (irritative) subscore - 4 weeks-1.27 ± 0.14-0.76 ± 0.14
IPSS storage (irritative) subscore - 12 weeks-1.74 ± 0.14-1.34 ± 0.14
IPSS storage (irritative) subscore - 26 weeks-2.00 ± 0.15-1.66 ± 0.15
IPSS voiding (obstructive) subscore - 4 weeks-2.65 ± 0.19-1.47 ± 0.19
IPSS voiding (obstructive) subscore - 12 weeks-3.41 ± 0.21-2.37 ± 0.21
IPSS voiding (obstructive) subscore - 26 weeks-3.50 ± 0.22-2.77 ± 0.22
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.007 (P-value is for IPSS storage (irritative) subscore - 4 weeks.) · Ls mean difference: -0.51 · 95% CI -0.87 to -0.14The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.040 (P-value is for IPSS storage (irritative) subscore - 12 weeks.) · Ls mean difference: -0.41 · 95% CI -0.80 to -0.02The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.107 (P-value is for IPSS storage (irritative) subscore - 26 weeks) · Ls mean difference: -0.34 · 95% CI -0.75 to 0.07The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for IPSS voiding (obstructive) subscore - 4 weeks.) · Ls mean difference: -1.18 · 95% CI -1.69 to -0.68The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for IPSS voiding (obstructive) subscore - 12 weeks.) · Ls mean difference: -1.04 · 95% CI -1.62 to -0.46The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.015 (P-value is IPSS voiding (obstructive) subscore - 26 weeks.) · Ls mean difference: -0.73 · 95% CI -1.32 to -0.14The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
SecondaryChange in International Prostate Symptom Score (IPSS) Quality of Life Index From Baseline to 4, 12, and 26 Weeks

IPSS Quality of Life Index assesses participant response to the following question: "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?" Response options are Delighted (0); Pleased (1); Mostly satisfied (2); Mixed-about equally satisfied and dissatisfied (3); Mostly dissatisfied (4); Unhappy (5); Terrible (6), with a total range of 0-6. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 12 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in International Prostate Symptom Score (IPSS) Quality of Life Index From Baseline to 4, 12, and 26 Weeks
units on a scaleTadalafilPlacebo
4 weeks-0.63 ± 0.07-0.32 ± 0.06
12 weeks-0.95 ± 0.07-0.76 ± 0.07
26 weeks-1.10 ± 0.08-0.92 ± 0.08
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 4 weeks.) · Ls mean difference: -0.32 · 95% CI -0.50 to -0.14The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.051 (P-value is for 12 weeks.) · Ls mean difference: -0.19 · 95% CI -0.38 to 0.00The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.107 (P-value is for 26 weeks.) · Ls mean difference: -0.17 · 95% CI -0.38 to 0.04The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
SecondaryChange in International Index of Erectile Function (IIEF) - Erectile Function Domain Scores From Baseline to 4, 12, and 26 Weeks

Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 12 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in International Index of Erectile Function (IIEF) - Erectile Function Domain Scores From Baseline to 4, 12, and 26 Weeks
units on a scaleTadalafilPlacebo
4 weeks3.71 ± 0.50-1.14 ± 0.51
12 weeks4.71 ± 0.560.63 ± 0.57
26 weeks4.71 ± 0.57-0.02 ± 0.60
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 4 weeks.) · Ls mean difference: 4.85 · 95% CI 3.49 to 6.21The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 12 weeks.) · Ls mean difference: 4.08 · 95% CI 2.55 to 5.60The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 26 weeks.) · Ls mean difference: 4.73 · 95% CI 3.15 to 6.31The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
SecondaryChange in International Index of Erectile Function (IIEF) - Overall Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks

Self-reported overall satisfaction over the past 4 weeks. IIEF-Overall Satisfaction is the sum of Questions 13 and 14 of IIEF questionnaire. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 12 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in International Index of Erectile Function (IIEF) - Overall Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks
units on a scaleTadalafilPlacebo
4 weeks0.91 ± 0.15-0.10 ± 0.15
12 weeks1.38 ± 0.160.31 ± 0.17
26 weeks1.61 ± 0.170.40 ± 0.18
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 4 weeks.) · Ls mean difference: 1.01 · 95% CI 0.61 to 1.40The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 12 weeks.) · Ls mean difference: 1.06 · 95% CI 0.61 to 1.51The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 26 weeks.) · Ls mean difference: 1.22 · 95% CI 0.74 to 1.69The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
SecondaryChange in International Index of Erectile Function (IIEF) - Intercourse Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks

Self-reported intercourse satisfaction over the past 4 weeks. IIEF-intercourse satisfaction is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 12 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in International Index of Erectile Function (IIEF) - Intercourse Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks
units on a scaleTadalafilPlacebo
4 weeks1.36 ± 0.24-0.46 ± 0.24
12 weeks1.68 ± 0.260.08 ± 0.27
26 weeks1.72 ± 0.27-0.26 ± 0.28
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 4 weeks.) · Ls mean difference: 1.82 · 95% CI 1.18 to 2.47The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 12 weeks.) · Ls mean difference: 1.59 · 95% CI 0.88 to 2.31The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 26 weeks.) · Ls mean difference: 1.98 · 95% CI 1.23 to 2.73The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
SecondaryChange in International Index of Erectile Function (IIEF) - Orgasmic Function Domain Scores From Baseline to 4, 12, and 26 Weeks

Orgasmic Function domain scores is the sum of Questions 9 and 10 from the IIEF questionnaire. Scores range from 0 (low/no orgasm) to 5 (high orgasm) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher total scores indicate higher orgasm. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 12 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in International Index of Erectile Function (IIEF) - Orgasmic Function Domain Scores From Baseline to 4, 12, and 26 Weeks
units on a scaleTadalafilPlacebo
4 weeks0.90 ± 0.22-0.63 ± 0.23
12 weeks1.08 ± 0.230.18 ± 0.24
26 weeks0.89 ± 0.24-0.18 ± 0.25
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 4 weeks.) · Ls mean difference: 1.53 · 95% CI 0.92 to 2.13The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.006 (P-value is for 12 weeks.) · Ls mean difference: 0.90 · 95% CI 0.27 to 1.54The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = 0.002 (P-value is for 26 weeks.) · Ls mean difference: 1.07 · 95% CI 0.41 to 1.74The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
SecondaryChange in International Index of Erectile Function (IIEF) - Sexual Desire Domain Scores From Baseline to 4, 12, and 26 Weeks

Sexual desire domain scores is the sum of Questions 11 and 12 from the IIEF questionnaire. Scores range from 1 (low/no desire) to 5 (high desire) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher desire. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 12 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in International Index of Erectile Function (IIEF) - Sexual Desire Domain Scores From Baseline to 4, 12, and 26 Weeks
units on a scaleTadalafilPlacebo
4 weeks0.46 ± 0.12-0.47 ± 0.12
12 weeks0.56 ± 0.13-0.23 ± 0.13
26 weeks0.71 ± 0.13-0.05 ± 0.14
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 4 weeks.) · Ls mean difference: 0.93 · 95% CI 0.61 to 1.25The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 12 weeks.) · Ls mean difference: 0.79 · 95% CI 0.44 to 1.14The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for 26 weeks.) · Ls mean difference: 0.76 · 95% CI 0.39 to 1.13The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
SecondaryPatient Global Impression of Improvement (PGI-I) at 26 Weeks

Patient Global Impression of Improvement (PGI-I) measures the participant's perception of improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).

Time frame:
26 weeks
Reported as:
Number · participants
Patient Global Impression of Improvement (PGI-I) at 26 Weeks
participantsTadalafilPlacebo
1 = Very much better2129
2 = Much better12482
3 = Little better102112
4 = No change4952
5 = A little worse105
6 = Much worse27
7 = Very much worse11
Statistical analysis
  • Tadalafil vs Placebo · Cochran-Mantel-Haenszel · p = 0.034 (P-value is for overall distribution of responses.)Adjusted for baseline lower urinary tract symptoms (LUTS) severity.
SecondaryTreatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 26 Weeks

The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. It consists of 10 items on a Likert-like scale with scores ranging from 1 (higher satisfaction) to 5 (lower satisfaction), 1 item with score ranging from 0 (higher satisfaction) to 5 (lower satisfaction), and 2 yes/no questions. The mean score for each participant ranges from 0.9 (higher satisfaction) to 5.0 (lower satisfaction). Data presented are the average of mean scores for each treatment group.

Time frame:
26 weeks
Reported as:
Mean · units on a scale
Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 26 Weeks
units on a scaleTadalafilPlacebo
Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 26 Weeks2.0 ± 0.632.1 ± 0.66
Statistical analysis
  • Tadalafil vs Placebo · Van Elteren test · p = 0.031Van Elteren test was stratified by region.
SecondaryClinician Global Impression of Improvement (CGI-I) at 26 Weeks

Clinician Global Impression of Improvement (CGI-I) measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).

Time frame:
26 weeks
Reported as:
Number · participants
Clinician Global Impression of Improvement (CGI-I) at 26 Weeks
participantsTadalafilPlacebo
1 = Very much improved2322
2 = Much improved12997
3 = Minimally improved98106
4 = No change4748
5 = Minimally worse510
6 = Much worse56
7 = Very much worse01
Statistical analysis
  • Tadalafil vs Placebo · Cochran-Mantel-Haenszel · p = 0.328 (P-value is for overall distribution of responses.)Adjusted for baseline lower urinary tract symptoms (LUTS) severity.
SecondaryChange in Post Void Residual (PVR) Volume From Baseline to 26 Weeks

Postvoid Residual Volume (PVR) is determined using a portable, calibrated ultrasound device. It consists of the average of a minimum of 3 scans where the residual bladder volume was calculated by averaging the most accurate of the 3 imaging attempts.

Time frame:
Baseline, 26 weeks
Reported as:
Mean · milliliters (mL)
Change in Post Void Residual (PVR) Volume From Baseline to 26 Weeks
milliliters (mL)TadalafilPlacebo
Change in Post Void Residual (PVR) Volume From Baseline to 26 Weeks-24.8 ± 73.08-23.1 ± 66.15
Statistical analysis
  • Tadalafil vs Placebo · Wilcoxon Rank-Sum test · p = 0.157
SecondaryChange in International Index of Erectile Function (IIEF) Question 3 and 4 Scores From Baseline to 4, 12, and 26 Weeks

IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.

Time frame:
Baseline, 4 weeks, 12 weeks, 26 weeks
Reported as:
Least squares mean · units on a scale
Change in International Index of Erectile Function (IIEF) Question 3 and 4 Scores From Baseline to 4, 12, and 26 Weeks
units on a scaleTadalafilPlacebo
Question 3 - 4 weeks0.42 ± 0.09-0.32 ± 0.09
Question 3 - 12 weeks0.72 ± 0.090.04 ± 0.09
Question 3 - 26 weeks0.68 ± 0.10-0.07 ± 0.10
Question 4 - 4 weeks0.49 ± 0.09-0.21 ± 0.09
Question 4 - 12 weeks0.74 ± 0.090.13 ± 0.09
Question 4 - 26 weeks0.68 ± 0.100.06 ± 0.10
Statistical analysis
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for Question 3 - 4 weeks.) · Ls mean difference: 0.74 · 95% CI 0.49 to 0.98The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for Question 3 - 12 weeks.) · Ls mean difference: 0.68 · 95% CI 0.43 to 0.93The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for Question 3 - 26 weeks.) · Ls mean difference: 0.75 · 95% CI 0.48 to 1.02The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for Question 4 - 4 weeks.) · Ls mean difference: 0.71 · 95% CI 0.46 to 0.95The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for Question 4 - 12 weeks.) · Ls mean difference: 0.61 · 95% CI 0.36 to 0.85The Kenward-Roger approximation was used to estimate denominator degrees of freedom.
  • Tadalafil vs Placebo · Mixed Model Repeated Measures Analysis · p = <0.001 (P-value is for Question 4 - 26 weeks.) · Ls mean difference: 0.62 · 95% CI 0.35 to 0.89The Kenward-Roger approximation was used to estimate denominator degrees of freedom.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Screening-Washout and Placebo Lead-In—1/1,070 (0.1%)153/1,070 (14.3%)
Tadalafil—9/345 (2.6%)105/345 (30.4%)
Placebo—5/350 (1.4%)94/350 (26.9%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventScreening-Washout and Placebo Lead-InTadalafilPlacebo
CholangitisHepatobiliary disorders0/10701/3450/350
Device related infectionInfections and infestations0/10701/3450/350
GastroenteritisInfections and infestations0/10701/3450/350
HyperglycaemiaMetabolism and nutrition disorders0/10701/3450/350
Back painMusculoskeletal and connective tissue disorders0/10701/3450/350
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/10701/3450/350
OsteoarthritisMusculoskeletal and connective tissue disorders0/10701/3450/350
Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/10701/3450/350
Ischaemic strokeNervous system disorders0/10701/3450/350
Urinary retentionRenal and urinary disorders0/10701/3451/350
Most frequent other events
Showing 10 of 220
Most frequent other events
EventScreening-Washout and Placebo Lead-InTadalafilPlacebo
Back painMusculoskeletal and connective tissue disorders6/107015/3456/350
HeadacheNervous system disorders12/107012/34512/350
DyspepsiaGastrointestinal disorders7/10708/3452/350
InfluenzaInfections and infestations6/10708/3458/350
DiarrhoeaGastrointestinal disorders5/10705/3456/350
NasopharyngitisInfections and infestations13/10705/3453/350
Pain in extremityMusculoskeletal and connective tissue disorders5/10705/3455/350
DysuriaRenal and urinary disorders1/10701/3455/350
Erectile dysfunctionReproductive system and breast disorders0/10701/3455/350
Gastric ph decreasedInvestigations0/10704/3451/350

Baseline characteristics

Age Continuous
Age Continuous(years)TadalafilPlaceboTotal
Mean63.8 ± 7.5063.6 ± 7.8563.7 ± 7.68
Sex: Female, Male
Sex: Female, Male(Participants)TadalafilPlaceboTotal
Female000
Male345350695
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TadalafilPlaceboTotal
Hispanic or Latino459
Not Hispanic or Latino394180
Unknown or Not Reported302304606
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TadalafilPlaceboTotal
American Indian or Alaska Native333770
Asian516
Native Hawaiian or Other Pacific Islander000
Black or African American61521
White298296594
More than one race314
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)TadalafilPlaceboTotal
United States434689
Greece181230
Turkey261945
Russian Federation323769
Italy212546
France21930
Mexico333770
Canada302858
Argentina464187
Belgium71623
Poland323971
Brazil121325
Germany242852
Lower urinary tract symptoms (LUTS) severity
Lower urinary tract symptoms (LUTS) severity(participants)TadalafilPlaceboTotal
Moderate (IPSS<20)238235473
Severe (IPSS≥20)106114220
Unknown112
Peak urine flow rate
Peak urine flow rate(participants)TadalafilPlaceboTotal
<10 milliliters/second (mL/sec)154169323
10-15 mL/sec190180370
>15 mL/sec112
Postvoid residual volume (PVR)
Postvoid residual volume (PVR)(milliliters (mL))TadalafilPlaceboTotal
Mean65.5 ± 60.6962.6 ± 59.5764.1 ± 60.10

7 further baseline measures are reported on the registry.

08

Study locations

65 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Davis, California 95616, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fresno, California 93720, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Laguna Hills, California 92367, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Long Beach, California 90806, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vacaville, California 95688, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sarasota, Florida 34237, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Petersburg, Florida 33710, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33407, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shreveport, Louisiana 71106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Georgetown, Texas 78626, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1060AAA, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Córdoba, X5016KEH, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1090, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edegem, 2650, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gent, 9000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kortrijk, 8500, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto Alegre, 90610-970, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio De Janeiro, 20551-030, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 04262-000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T2W 1P9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Abbottsford, British Columbia V2S 3N5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Surrey, British Columbia V3V 1N1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Victoria, British Columbia V8V 3N1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kitchener, Ontario N2N 3B9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    North York, Ontario M6A 3B5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thunder Bay, Ontario P7E 6E7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pointe Claire, Quebec H9R 4S3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trois-Rivieres, Quebec G9A3V7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44093, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nimes, 30029, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orleans, 45067, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suresnes, 92150, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vandoeuvre Les Nancy, 54511, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13465, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hettstedt, 06333, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04109, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Muehlacker, 75417, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 10552, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heraklion, 71110, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Larissa, 41221, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patras, 26500, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thessaloniki, 56429, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20122, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Napoli, 80131, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00189, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sassari, 07100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chihuahua, 31000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Colima, 28000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44610, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 06700, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saltillo, 25210, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tlalpan, 14000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bydgoszcz, 85-168, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kutno, 99-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 61-251, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zabrze, 41-800, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 109472, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rostov-On-Don, 344011, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 197136, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saratov, 410026, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adana, 1330, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Denizli, 06111, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Istanbul, 34303, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Izmir, 35340, Turkey
09

References and documents

Publications

  • Glina S, Roehrborn CG, Esen A, Plekhanov A, Sorsaburu S, Henneges C, Buttner H, Viktrup L. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med. 2015 Jan;12(1):129-38. doi: 10.1111/jsm.12714. Epub 2014 Oct 29. PubMed 25353053 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Feb 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2010
First posted
Jun 9, 2010
Start
Sep 2010
Primary completionActual
Feb 2012
CompletionActual
May 2012
Results first posted
Feb 27, 2013
Last update
Feb 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01139762
Responsible party
Sponsor
First posted
Jun 9, 2010
Start date
Sep 2010
Primary completion
Feb 2012
Completion
May 2012
Results posted
Feb 27, 2013
Last update
Feb 27, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion